Open AccessReal world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience
Author(s) -
Ma Carmen Areses Manrique,
J. Mosquera Martinez,
Jorge García González,
Francisco Javier Afonso Afonso,
Martín Lázaro Quintela,
Natalia Fernández Núñez,
Cristina Azpitarte Raposeiras,
Margarita Amenedo Gancedo,
Lucía Santomé Couto,
M.R. García Campelo,
J. Iglesias,
Alexandra Cortegoso,
Rafael Simó,
J. Casal Rubio,
Begoña Campos Balea,
Iria Carou Frieiro,
Guillermo Alonso-Jáudenes Curbera,
Urbano Anido Herranz,
Jesús García Mata,
José Luis Fírvida Pérez
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.04.03
Subject(s) - medicine , nivolumab , lung cancer , anaplastic lymphoma kinase , oncology , progressive disease , stage (stratigraphy) , adenocarcinoma , response evaluation criteria in solid tumors , cancer , clinical trial , performance status , immunotherapy , gastroenterology , disease , paleontology , biology , malignant pleural effusion
Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivolumab in pretreated NSCLC.